Aimmune Therapeutics Inc.
www.aimmune.com
Latest From Aimmune Therapeutics Inc.
As US FDA Settles Into Teleworking, Will Application Reviews Be Affected?
Productivity may suffer under coronavirus-mandated telework despite workforce diligence, experts say.
Bad For Pharma: Sales Reps And Patients Are Staying Home
Industry is limiting face-to-face interactions between sales reps and physicians, and some patients are sitting out visits, amid the COVID-19 outbreak. That poses big business challenges for pharma.
Coronavirus Update: Drug Launches Could Be Hit, New Twist In CureVac Controversy, Moderna Doses First Patient
As western Europe and the US roll out the next wave of lockdown measures to limit the spread of COVID-19, biopharma is continuing efforts to accelerate therapies and vaccines, including Moderna starting Phase I trials.
Palforzia Peanut Allergy Immunotherapy: Aimmune CEO On REMS Restrictions, Manufacturing
Aimmune CEO Jayson Dallas tells the Pink Sheet how physicians and patients are being certified to use Palforzia and how the product's food-based manufacturing process is actually an advantage.
Company Information
- Industry
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
-
Pharmaceuticals
- Vaccines
- Therapeutic Areas
- Immune Disorders
- Alias(es)
- Allergen Research Corp.
- Ownership
- Public
- Headquarters
-
Worldwide
-
North America
-
USA
-
USA
-
North America
- Parent & Subsidiaries
- Aimmune Therapeutics Inc.
- Senior Management
-
Jayson Dallas, Pres. & CEO
Eric Bjerkholt, CFO
Jeffrey H Knapp, PhD, COO
Daniel C Adelman, MD, CMO
Mary Rozenman, PhD, SVP, Corp. Dev. & Strategy - Contact Info
-
Aimmune Therapeutics Inc.
Phone: (650) 614-5220
8000 Marina Blvd.
Ste. 300
Brisbane, CA 94005
USA
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice